GILD vs ILMN: fair value comparison
Gilead Sciences, Inc. and Illumina, Inc. · Updated 2026-09-12
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, GILD currently sits closer to the top of our discount ranking.
| GILD | ILMN | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $143.72 | $207.13 |
| 12-month range | $119.79–$150.03 | $102.26–$207.13 |
| Sector rank | #102 of 113 Healthcare | #106 of 113 Healthcare |
| Quality grade | C | C |
| Leverage | High | Moderate |
| Margin trend | Expanding | Stable |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Uptrend |
| DCF cross-check | Undervalued | — |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: GILD fair value analysis · ILMN fair value analysis